These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11749739)

  • 1. How Barr managed to kill Eli Lilly's patent on Prozac.
    Pabst PL
    Tissue Eng; 2001 Dec; 7(6):843-4. PubMed ID: 11749739
    [No Abstract]   [Full Text] [Related]  

  • 2. Court dismisses Eli Lilly's case against generic drug makers.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2001; 6(1-2):60. PubMed ID: 11837032
    [No Abstract]   [Full Text] [Related]  

  • 3. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 4. Promega changes tack in battle over patent.
    Knight J
    Nature; 2003 Nov; 426(6965):373. PubMed ID: 14647346
    [No Abstract]   [Full Text] [Related]  

  • 5. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 6. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 7. International patent protection for HIV-related therapies: patent attorney's perspective.
    Pavento LC; Greene JL; McDonald JK
    Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935
    [No Abstract]   [Full Text] [Related]  

  • 8. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 9. The Claritin case: how one firm played the patent game.
    Novak V
    Time; 1999 Nov; 154(21):42. PubMed ID: 10622840
    [No Abstract]   [Full Text] [Related]  

  • 10. A day late and a few million dollars short.
    Goldenson D
    Nat Biotechnol; 2009 Jun; 27(6):538-41. PubMed ID: 19513055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 12. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 13. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746
    [No Abstract]   [Full Text] [Related]  

  • 14. Lilly goes off Prozac.
    Simons J
    Fortune; 2004 Jun; 149(13):179-80, 182, 184. PubMed ID: 15241951
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 16. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 17. Listening to generic Prozac: winners, losers, and sideliners.
    Druss BG; Marcus SC; Olfson M; Pincus HA
    Health Aff (Millwood); 2004; 23(5):210-6. PubMed ID: 15371387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cipro patent and bioterrorism.
    Kaye KS; Kaye D
    Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent law.
    Henry D; Lexchin J
    Lancet; 2003 Mar; 361(9362):1059. PubMed ID: 12660088
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.